Rigel Pharma Q1 net loss narrows to $13.5M; TAVALISSE sales up 38% to $22.3M

RIGEL PHARMACEUTICALS INC

2023-Q1 EPS reported -$0.08 revenue$26,070,000

Net loss of $13.5M ($0.08/sh) improved from $27.4M ($0.16) in Q1 2022.
Total revenue $26.1M: TAVALISSE $22.3M (+38% YoY), REZLIDHIA $1.5M (first full quarter).
Shipped 2,256 TAVALISSE bottles to patients (highest quarter); 109 REZLIDHIA bottles shipped.
Accessed $20M term loan from MidCap; cash and investments $58.7M as of March 31.
Partner Kissei launched TAVALISSE in Japan; Lilly to begin Phase 2a trial of R552 in RA in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 2, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) announced certain financial results for its first quarter ended March 31, 2023. A copy of Rigel’s press release, titled “Rigel Reports First Quarter 2023 Financial Results and Provides Business Update,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-055028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.